NCT05442151

Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Tadashi Watabe · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

PET / CT examination using \[18F\] FAPI-74 is performed on patients diagnosed with malignant tumor, and the pathological condition is determined by comparing with FDG-PET/CT examination of conventional diagnostic imaging.

Detailed description

Cancer stroma accounts for more than 90% of all tumors, and cancer-related fibroblasts (CAFs) play an important role in the growth and progression of cancer. FAP expressed in CAF has been found to be expressed in many cancers, and \[68Ga\] FAPI-04 and \[18F\] FAPI-74, which are PET diagnostic agents for FAP ligand FAPI, have been used all over the world. The purpose of this study is to perform PET / CT using \[18F\] FAPI-74 injection for patients diagnosed with malignant tumors, mainly pancreatic cancer and gastric cancer to evaluate the pathology in detail by comparing with the FDG-PET/CT.

Conditions

• Neoplasms

Interventions

Type	Name	Description
DRUG	PET/CT ([F-18]FAPI-74)	PET/CT using \[18F\] FAPI-74 injection

Timeline

• Start date: 2022-05-09
• Primary completion: 2026-03-31
• Completion: 2026-03-31
• First posted: 2022-07-01
• Last updated: 2025-07-31

Locations

1 site across 1 country: Japan